2,3,5,6-Tetramethylpyrazine improves diet-induced whole-body insulin resistance via suppressing white adipose tissue lipolysis in mice

Biochem Biophys Res Commun. 2020 Nov 19;532(4):605-612. doi: 10.1016/j.bbrc.2020.08.099. Epub 2020 Sep 6.

Abstract

Ectopic lipid accumulation in skeletal muscle and liver arises when nutrient storage systems are exposed to chronic energy surplus, leading to whole-body insulin resistance and metabolic disorders. One recent study has shown 2,3,5,6-tetramethylpyrazine (TMP), highly enriched in roasted foodstuffs, such as cocoa and peanuts, significantly decreases blood lipids levels and ameliorates ApoE-defect induced atherosclerosis suggesting a potent role of TMP in lipid dysregulation improvement. Here, we evaluated the impact of TMP treatment on high fat diet (HFD)-induced insulin resistance. Using hyperinsulinemic-euglycemic mouse clamp, we demonstrated 4-week TMP treatment improved whole-body insulin resistance in HFD-fed mice through suppressing lipolysis in white adipose tissue associated with reduced triglyceride in liver and improved glucose uptake in skeletal muscle. Collectively, our work provides proof-of-concept data to support the development of white adipose tissue-targeted medicine for the treatment of metabolic disorder.

Keywords: Glucose uptake; Lipolysis; TMP; Whole-body insulin resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue, White / drug effects*
  • Adipose Tissue, White / metabolism
  • Animals
  • Diet, High-Fat / adverse effects
  • Fatty Liver / chemically induced
  • Fatty Liver / drug therapy
  • Glucose / metabolism
  • Insulin Resistance*
  • Lipolysis / drug effects
  • Male
  • Mice
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / metabolism
  • Pyrazines / therapeutic use*

Substances

  • Pyrazines
  • Glucose
  • tetramethylpyrazine